Moreover, in murine tumor models, targeting CCR8 with a CCR8-neutralizing mAb (mIgG2b) induces a protective immunity and enhances the vaccine-induced response to CRC in CT26 and MC38 subcutaneous tumor models through the inhibition of CCR8+ Treg recruitment without impacting the peripheral FOXP3+ Treg subsets [96]. The gene discussed is CCR8; the disease is colorectal carcinoma.